Pyruvate & Glaucoma Protection
MyEyes is partnering with Dr. Louis Pasquale of Mount Sinai to investigate whether pyruvate supplementation can help protect against glaucoma progression — and we're inviting our community to participate.
Approximately 35 participants · Home IOP monitoring with iCare HOME2
Why This Study Matters
Current glaucoma treatment focuses almost entirely on lowering intraocular pressure (IOP). But emerging research suggests that metabolic factors — how your cells produce and use energy — may play a significant role in whether the optic nerve is resilient or vulnerable to damage.
Pyruvate is a naturally occurring molecule at the heart of cellular energy production. A landmark 2025 study published in eLife by Dr. Pasquale and colleagues analyzed over 117,000 participants in the UK Biobank and found that elevated levels of pyruvate, lactate, and citrate — all key metabolites in the glycolysis pathway — were associated with reduced glaucoma prevalence, even in individuals at high genetic risk.
The same study showed that pyruvate supplementation reduced glaucoma incidence in a genetic mouse model. This suggests a potential new avenue for glaucoma protection beyond IOP-lowering alone.
Lead Investigator
Dr. Louis Pasquale, MD, FARVO
One of the world's leading glaucoma researchers, Dr. Pasquale brings decades of experience in gene-environment interactions in eye disease.
Positions
- Professor of Ophthalmology, Icahn School of Medicine at Mount Sinai
- Vice Chair of Translational Ophthalmology Research, Mount Sinai Health System
- Site Chair, Department of Ophthalmology, Mount Sinai Hospital
Research Profile
- Continuously NIH-funded Principal Investigator since 2006
- Glaucoma Trustee, Association for Research in Vision and Ophthalmology (ARVO)
- Member, NIH National Advisory Eye Council
- Editorial boards: Journal of Glaucoma, Ophthalmology Glaucoma, American Journal of Ophthalmology
The Science So Far
Population Evidence: UK Biobank (2025)
117K+
Participants analyzed
4,658
Glaucoma cases studied
Protective
Higher pyruvate = lower glaucoma risk
Dr. Pasquale's team found that elevated glycolysis-related metabolites — pyruvate, lactate, and citrate — were significantly associated with reduced glaucoma prevalence, even among individuals with high genetic risk. A companion mouse model confirmed that pyruvate supplementation reduced disease incidence.
Pasquale LR, et al. “Pyruvate and Related Energetic Metabolites Modulate Resilience Against High Genetic Risk for Glaucoma.” eLife. 2025.
Clinical Evidence: Phase 2 Trial (2021)
A randomized Phase 2 trial at Columbia University tested nicotinamide and pyruvate supplementation in glaucoma patients and found significant short-term improvement in visual function — the first clinical demonstration of metabolic neuroprotection for glaucoma.
De Moraes CG, et al. “Nicotinamide and Pyruvate for Neuroenhancement in Open-Angle Glaucoma.” JAMA Ophthalmology. 2022.
Why This Is Special
As a MyEyes customer, you have a unique opportunity to participate in cutting-edge research with one of the world's top glaucoma researchers.
Trusted Partnership
Dr. Pasquale is a continuously NIH-funded researcher and one of the most published glaucoma scientists in the world. MyEyes is proud to support this research as a trusted technology partner.
Small & Focused
With approximately 35 participants, this is an intimate study where every participant's data matters. You'll be part of a select group contributing to groundbreaking glaucoma science.
Beyond IOP Lowering
This study explores a fundamentally new approach — supporting your optic nerve's cellular energy production, rather than only reducing pressure. It's the kind of research that could change how glaucoma is treated.
MyEyes Support
Study participants using home tonometry will receive the same hands-on support from our Patient Ambassadors that all MyEyes customers know and trust.
How to Participate
Express Interest
Contact our team by phone or email to let us know you're interested. We'll walk you through what to expect and answer any questions.
Eligibility Screening
The research team will review your eligibility based on your glaucoma diagnosis, treatment history, and other criteria. Your doctor may need to confirm your diagnosis.
Enrollment & Onboarding
Once approved, you'll receive study materials and be onboarded by the MyEyes team for any home monitoring components of the study.
Interested in Participating?
Space is limited to approximately 35 participants. Fill out the form below and our team will be in touch to discuss eligibility and next steps.
Frequently Asked Questions
What is pyruvate?
Pyruvate is a molecule your body produces naturally as part of cellular energy metabolism (glycolysis). It plays a central role in how cells generate the energy they need to function. Research suggests that boosting pyruvate levels may help protect the optic nerve cells that are damaged in glaucoma.
Is pyruvate safe?
Pyruvate is a naturally occurring substance in your body and is available as an over-the-counter supplement. It has been used in clinical trials with a well-documented safety profile. As with any study, the research team will closely monitor all participants.
Do I need to stop my current glaucoma medications?
No. This study is designed to complement your existing glaucoma treatment, not replace it. You should continue all medications prescribed by your doctor.
Do I need to be an existing MyEyes customer?
No. The study is open to eligible participants regardless of whether you are a current MyEyes customer. However, MyEyes customers who are already familiar with home tonometry may find the process especially seamless.
Will I need to travel for the study?
Details about study visits and remote participation options will be shared during the screening process. The home monitoring component uses the iCare HOME2, which can be done from your own home.
Is there any cost to participate?
Details about study costs, compensation, and provided materials will be discussed during the eligibility screening process.
References
- Pasquale LR, et al. Pyruvate and related energetic metabolites modulate resilience against high genetic risk for glaucoma. eLife. 2025. eLife
- De Moraes CG, et al. Nicotinamide and pyruvate for neuroenhancement in open-angle glaucoma: a phase 2 randomized clinical trial. JAMA Ophthalmology. 2022;140(1):11-18. doi:10.1001/jamaophthalmol.2021.4576
- ClinicalTrials.gov. Nicotinamide and pyruvate for open angle glaucoma: a randomized clinical study. NCT05695027
Be Part of Glaucoma's Next Chapter
Join a select group of participants working alongside one of the world's top glaucoma researchers. Space is limited.